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Therapeutic Strategies for Alzheimer Disease
Focus on Neuronal Reactivation of Metabolically Impaired Neurons
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Abstract: Based on several lines of evidence, it has been hypoth-
esized that decreased neuronal metabolic rate may precede cognitive
impairment, contributing to neuronal atrophy as well as reduced neu-
ronal function in Alzheimer disease (AD). Additionally, studies have
shown that stimulation of neurons through different mechanisms may
protect those cells from the deleterious effects of aging and AD, a
phenomenon we paraphrased as “use it or lose it.” Therefore, it is
attractive to direct the development of therapeutic strategies toward
stimulation of metabolic rate/neuronal activity to improve cognition
and other symptoms in AD. A number of pharmacological and non-
pharmacological approaches discussed here support the concept that
stimulation of the brain has beneficial effects and may, to a certain
degree, restore several aspects of cognition and other central func-
tions. For instance, the circadian system, which controls the
sleep/wake cycle, may be stimulated in AD patients by exposing them
to more light or transcutaneous nerve stimulation. We will also dis-
cuss a procedure that has been developed to culture human postmor-
tem brain tissue, which allows testing of the efficacy of putative
stimulatory compounds.
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A lzheimer disease (AD) is a multifactorial disease in whichage and the APOE4 allele are important risk factors. The
APOE4 genotype is associated with memory decline in cogni-
tively impaired elderly and is present in about 17% of all AD
patients.1–3 In addition, female gender is a risk factor, which
agrees with the more severe early cytoskeletal alterations pres-
ent in the nucleus basalis of Meynert (NBM) of women.4 His-
topathologically, AD is characterized by a large number of
neuritic plaques (NPs) as well as cytoskeletal changes that pre-
sent as neurofibrillary tangles (NFTs), neuropil threads, or
dystrophic neurites.5 Since these neuropathological changes
cannot be distinguished qualitatively from those appearing in
elderly nondemented subjects, it is still a controversial issue
whether these hallmarks are responsible for the clinical symp-
toms of dementia or are a byproduct of the disease.6 During
normal aging, cell loss is not a prominent phenomenon. In fact,
unaltered neuronal numbers have been reported in many brain
areas,7 and the loss of neocortical neurons over a lifespan was
estimated to be only 10%.8 Regeur et al.,9 using unbiased sam-
pling and counting methods, showed that despite the generally
observed cortical atrophy in AD, global neocortical neuronal
loss is not present, providing strong evidence that neuronal
shrinkage rather than cell death is a major phenomenon in this
neurodegenerative disorder.
Age-related memory disturbances and the loss of
memory in AD have been associated, at least partly, with cho-
linergic dysfunction and degenerative changes in the NBM,
which projects to the cerebral cortex.10 Indeed, neurotoxic le-
sions of the cholinergic system in experimental animals induce
performance deficits,11 and marked reductions in cholinergic
markers have been found in the cerebral cortex even at an early
stage of AD.12 Moreover, the number of neurons containing
choline acetyltransferase (ChAT) and the vesicular acetylcho-
line transporter correlates significantly with the severity of de-
mentia, as determined by the Mini-Mental State Examination
(MMSE).13 Despite these and related observations, neuronal
loss in the NBM appears less extensive than presumed earlier.
Here we focus on the NBM to examine the evidence that de-
creased neuronal activity via neuronal atrophy plays a role in
AD pathology, including a discussion of the possible contribu-
tion of reduced cellular metabolism and reduced neurotrophin
activity to this pathologic process. Additionally, we consider
the therapeutic possibilities of pharmacological and nonphar-
macological approaches to neuronal reactivation.
NEURONAL ATROPHY RATHER THAN LOSS IN
THE NBM
Estimations of neuronal loss in the NBM during normal
aging vary greatly, with decreases ranging from 23% to
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90%14–20 to no significant neuronal loss.21,22 Massive cell
death in the NBM was originally presumed to be one of the
major hallmarks of AD,14,16,18,23,24 and a clear loss of ChAT, a
marker of NBM neurons, was reported.25 However, it is of cru-
cial importance to distinguish loss of a cholinergic marker
from a loss of neurons. It has been presumed that the large
differences in cell loss that were reported may partly be due to
heterogeneity of different NBM subdivisions.26 Indeed, Vo-
gels et al.27 found an overall neuron loss in the NBM of only
10% in AD patients, while neuron loss varied from 0% in the
rostral to 36% in the caudal part of the NBM. However, re-
gional heterogeneity cannot be the only explanation for the
variable data reported. Even studies performed on one particu-
lar NBM subdivision showed considerable variation. For in-
stance, measurements performed in the NBM sub-area Ch4a
showed cell loss differences varying between 42% and
89%16,20 to no significant cell loss.25
The most likely explanation for the equivocal results
concerning neuronal loss in the NBM in AD is the use of dif-
ferent criteria for the size of counted cells. Mann et al.,16 for
instance, only counted cells meeting a minimum diameter re-
quirement and reported a 54% cell loss in the NBM, whereas
Pearson et al.25 counted all NBM neurons regardless of their
size and did not find any significant cell loss in the NBM. In-
deed, while the number of large neurons decreases, the number
of small neurons increases in the NBM in AD.15,27–29 The
combined data indicate that the majority of large neurons at-
rophy and lose their cholinergic markers but only a small sub-
set dies.
METABOLIC ACTIVITY IN THE NBM IN
RELATION TO APOE GENOTYPE
Neuronal atrophy is an indicator of decreased cellular
metabolism, which has been extensively studied as a contrib-
uting factor to AD. The size of the Golgi apparatus (GA), part
of the protein processing and targeting machinery, has been
used as a sensitive parameter for measuring changes in neuro-
nal metabolic activity.30,31 GA size was, therefore, used in our
studies to monitor metabolic activity changes in the NBM in
aging and AD.
A strong decrease in GA size (49%) was observed in
AD, suggesting that the capacity of NBM neurons to process
and target proteins decreases dramatically in the disease.32,33
This notion is consistent with previous demonstrations of de-
creased nucleolus volume16,34 and reduced ChAT and cholin-
esterase activity in the NBM in AD.17,18,35–37 This reduction in
metabolic rate is amplified in those AD patients with either one
or two APOE4 alleles,33 and this finding is in full agreement
with the more severe cholinergic deficit in the temporal cortex
observed in AD patients with one or two APOE4 alleles.38
Postmortem temporal cortex tissue obtained from cog-
nitively normal subjects with an APOE4 allele showed com-
promised cholinergic activity compared with tissue from sub-
jects without this allele.39 Therefore, we currently are investi-
gating whether neuronal metabolism is already lower in the
NBM of APOE4-positive, cognitively normal subjects without
AD pathology (i.e., Braak stage 0–II), compared with APOE4
negative controls. Using the size of the GA as a measure of
neuronal metabolism, this indeed appears to be the case (E.J.G.
Dubelaar et al., unpublished observation), lending support to a
role for decreased metabolism as a risk factor in AD.
NEUROTROPHIN RECEPTOR CHANGES IN
THE NBM
Neurotrophins, including nerve growth factor (NGF),
promote neuronal metabolism and function, suggesting that
disruption of neurotrophin signaling could play a role in the
neuronal atrophy seen in AD. In the basal forebrain complex,
which includes the NBM, both low affinity neurotrophin re-
ceptors (p75)40,41 and high affinity neurotrophin receptors42
are present. All three family members of the high affinity re-
ceptors, the tyrosine receptor kinases (trks) A, B, and C, are
found in NBM neurons.43–45 In the NBM, levels of NGF and
NGF receptors decrease during aging and even more so in
AD.46,47 Studies from our group show that all three types of
trks colocalize in NBM neurons and are decreased at varying
levels in AD (trkA levels < trkC < trkB)45 (Fig. 1). TrkA
mRNA levels decrease markedly in AD,48 and reduction in
trkA expression has subsequently been confirmed.49,50 More-
FIGURE 1. Graph depicting the proportion of neurons stained
by trk antibodies in AD patients and controls in the nucleus
basalis of Meynert (NBM). Note the strong reduction in the
proportion of trkA-expressing neurons in Alzheimer patients,
which is followed by trkB and trkC (*P = 0.00001, **P = 0.009,
***P = 0.004). (Data from Salehi et al.45) Reprinted from Neu-
roscience, V75, Salchi A, Verhaagen J, Dijkhuizen PA, et al.,
“Co-localization of high-affinity neurotrophin receptors in
nucleus basalis of Meynert neurons and their differential re-
duction in Alzheimer’s disease.” 373–387, 1996, with permis-
sion from Elsevier.
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over, it was shown that a loss of immunoreactive trkA neurons
occurs in individuals with mild cognitive impairment (MCI)
without dementia, to the same degree as in early AD.51 The
reduction in trk receptors may underlie the diminished NGF
levels in the NBM (due to a decrease in NGF retrograde trans-
port), leading to decreased metabolism and function of NBM
neurons. Indeed, a defect in retrograde transport of NGF in the
NBM of AD patients has been observed.47,52
In addition to changes in levels of the high affinity trk
receptors, we have found that the low affinity pan-neuro-
trophin receptor, p75, showed significantly decreased levels
both in cell bodies and in fibers of the NBM of AD patients.53
It thus appears that both high and low affinity neurotrophin
receptors are decreased in the NBM of AD patients, with re-
ductions in both receptor types possibly contributing to the de-
fect in NGF retrograde transport. Yet, this defect also may be
related to cytoskeletal changes in the NBM that are presumed
to hamper axonal transport in AD.54
The precise manner in which decreased neuronal meta-
bolic activity,32 cytoskeletal changes,54 loss of trk and p75 re-
ceptors,45,53 and failed NGF retrograde transport55 are related
to the neuronal atrophy and diminished function of the NBM
neurons should be studied further. While a clear role for NGF
therapy in AD remains to be elucidated, a few AD patients
treated with low doses of NGF infused into the cerebrospinal
fluid experienced several serious side effects, including pain
and weight loss. The pain dissipated shortly after NGF infu-
sion was halted and was followed by weight gain.56,57 Another
approach that currently is being studied in AD patients is NGF
gene therapy, which almost completely reverses the loss of
NBM neurons in rhesus monkeys.58
DECREASED NEURONAL ACTIVITY IS A
WIDESPREAD PHENOMENON IN AD
Various observations in addition to those mentioned
above for the NBM indicate that decreased neuronal activity is
a widespread, essential characteristic of AD, either as a risk
factor or as a direct pathogenic factor,59 while a high or en-
hanced neuronal activity would protect against the degenera-
tive changes of aging or AD, a hypothesis we paraphrased as
“use it or lose it.”60 Although a comprehensive review of the
data is beyond the scope of this article (for review see Swaab et
al.6), we will briefly discuss some of the more salient findings.
The report that the postmortem AD brain shows a lower total
amount of protein,61 a clear reduction in total cytoplasmic
RNA62–64 and messenger RNA,65–67 a smaller cell size (e.g.,
the somatostatin neurons in the cortex),68 and a small size of
the neuronal GA32,69,70 are all indications of neuronal atrophy
and decreased metabolic activity in AD. These findings agree
with the observed reduction in glucose metabolism found in
the AD brain, particularly in the temporal and parietal lobes, as
shown by positron emission tomography.71–74 Moreover, de-
creases in regional cerebral glucose metabolism as measured
by positron emission tomography in the temporoparietal, pre-
frontal, and occipital cortices have been correlated with a
change in MMSE score in probable AD patients, providing
further evidence that clinical deterioration and metabolic im-
pairment are closely related.75
METABOLIC RATE UNCHANGED BY
NEUROFIBRILLARY TANGLES AND
NEURITIC PLAQUES
Since the finding of decreased metabolic rate in affected
brain areas in AD, the two major questions concerning the
pathogenesis of AD have been (1) whether the presence of NPs
or NFTs in AD is related to decreased neuronal activity in vari-
ous brain areas and, if so, (2) whether these neuropathological
hallmarks induce decreased metabolic rate or vice versa. Al-
ternatively, neuropathological changes and a decreased meta-
bolic rate could occur independently. Our research supports
the latter possibility.
To study the causality of the relationship between NPs
and NFTs and decreased metabolic activity, we compared
metabolic activity (by measuring GA size) of CA1 neurons
that contained NFTs to those that lacked this neuropathologi-
cal feature. Since we found no apparent difference in the size
of the GA between these two groups of neurons, the presence
of NFTs does not seem to cause an extra decrease in the gen-
eral metabolic rate of a neuron.69 So, although NFTs and de-
creased metabolic activity are present in the same brain area
(i.e., CA1), they do not appear to be causally related. This ob-
servation is in agreement with Gertz et al.,76 who showed that
the presence of intraneuronal NFTs in the CA1 area of the hip-
pocampus is not related to another parameter of general meta-
bolic activity (i.e., nucleolar or cell size). These observations,
however, certainly do not exclude the possibility that NFTs
may decrease the production of specific compounds. Indeed,
Hätanpää et al.77 reported that cytochrome oxidase subunit III
mRNA is decreased in NFT-bearing neurons.
NPs are considered by some investigators as later stages
of amorphous plaques.78 Because of extensive damage to the
neuropil in the vicinity of NPs, they are also called “malig-
nant” plaques.79 Although it is still a matter of controversy,
many investigators believe that the -amyloid content of the
core plaque is neurotoxic and induces neural degeneration.
However, unlike the case of NFTs, there is no clear relation-
ship between the number of NPs and the severity of dementia,
which may call into question whether the neurotoxic effects of
NPs are a major pathogenetic mechanism in AD. If NPs indeed
contain neurotoxic compounds, one would expect that the
closer a neuron is situated to an NP, the lower its metabolic
rate. Our experiments do not support such a mechanism, as
there appears to be no relationship between the metabolic ac-
tivity of neighboring neurons and either the density of NPs or
the distance to each NP.33 Therefore, our findings do not sup-
port the notion that neurotoxicity of NPs causes decreased neu-
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ronal metabolism but rather suggest decreased neuronal me-
tabolism and NP neurotoxicity are independent phenomena.
REACTIVATION AS A MEANS OF RESTORING
NEURONAL FUNCTION IN AD
As this review has discussed, there appears to be reduced
neuronal metabolic activity in various brain areas in AD pa-
tients. Consequently, one may assume that restoration of neu-
ronal activity, either by pharmacological or nonpharmacologi-
cal approaches, would decrease cognitive impairment.6,60 Al-
though it is not yet clear whether decreased metabolic activity
is a primary process in the pathogenesis of AD, recent data
show that reactivation of neurons is possible in the elderly and,
in principle, beneficial to AD patients.
Pharmacological Approaches to
Neuronal Reactivation
One of the neurotransmitter systems clearly affected in
AD is the cholinergic system. Cholinesterase inhibitors
(ChEIs) enhance acetylcholine content in the synaptic cleft and
are associated with positive effects on cognitive function.10 In
some cases, the partial restoration of acetylcholine receptor
functioning via ChEIs has paralleled increased cerebral blood
flow and glucose metabolism.80 The beneficial cognitive ef-
fects of ChEIs may involve increased neuronal metabolism
and, therefore, may increase neuronal activity. An agent in an-
other drug class, Neotrofin, is a reported inducer of neuro-
trophins and may confer memory improvement in AD patients
via the induction of metabolic changes in various brain areas.81
Hormone therapy also is under investigation, as estrogen was
shown to significantly increase glucose metabolism in the lat-
eral temporal region of nondemented elderly people.82 Epide-
miological evidence indicated that estrogen replacement
therapy in postmenopausal women was associated with a
lower risk and/or delayed onset of AD83; however, randomized
controlled trials in AD patients have shown mixed results.83
Nonpharmacological Approaches to
Neuronal Reactivation
Engagement in both intellectual and leisure activities
and/or the participation in cognitively stimulating activities
may reduce the risk of AD.84–86 The mechanism behind the
concept of increased brain reserve through environmental
stimulation, also termed by us as “use it or lose it,”60 is not well
understood; however, important contributions have been
made, including those of Snowdon and colleagues through
their study of aging and disease in religious clergy (the “Nun
Study”).87 In one analysis, the idea density in subjects’ auto-
biographies was found to predict within about 85% to 90%
accuracy which individuals would present with AD nearly 60
years later (low idea density was associated with AD). One
interpretation of this finding is that early cognitively stimulat-
ing environmental factors may well lead to better brain func-
tion and reserve, lowering risk for AD.
To directly test the effects of neuronal stimulation, vari-
ous types of peripheral nerve stimulation (i.e., transcutaneous
electrical nerve stimulation [TENS], tactile nerve stimulation,
and a combination of both types of stimuli) were used to assess
the effects of increased somatosensory input on memory, and
on independent and affective functioning of patients in rela-
tively early stages of AD.88–92 These studies show that, com-
pared to controls who received a placebo treatment, various
aspects of nonverbal short-term memory, nonverbal and verbal
long-term memory, and word fluency of stimulated AD pa-
tients improved. More specifically, these improvements imply
that after stimulation patients were better capable of learning
new material, retrieving familiar, categorized information
from their memory store, and storing, reversing, and reproduc-
ing nonverbal information. With respect to independent and
affective functioning, stimulated patients participated more in-
dependently in daily life, showed a better personal orientation
and orientation in place, and enhanced their social interaction
with fellow residents. In addition, stimulated patients felt less
withdrawn, irritable, moody, dejected, and gloomy and ap-
peared to be more active and alert, possibly resulting in de-
creased forgetfulness. In these studies, the therapist was pres-
ent during both the peripheral stimulation of the experimental
group and the placebo treatment of the control group; there-
fore, an effect of interpersonal communication could not be
excluded. Consequently, it was examined whether TENS, in
the absence of a therapist, could also have positive effects on
the cognitive, independent, and affective functioning of AD
patients.92 The results show that the improvements in nonver-
bal short- and long-term memory, verbal long-term memory,
and word fluency are due solely to the electrical stimulus itself.
Furthermore, stimulated patients participated more indepen-
dently in activities of daily life; however, TENS performed in
the absence of a therapist did not appear to have a beneficial
effect on patients’ affective functioning. Another finding was
that the circadian rest-activity rhythm of stimulated AD pa-
tients improved, implying an increase in the strength of cou-
pling to Zeitgebers (i.e., environmental cues).93 Of note, the
majority of the effects of peripheral nerve stimulation, both in
the presence and absence of the therapist, could not be main-
tained during a treatment-free period of 6 weeks.
In the above-mentioned studies, TENS was applied to
patients in a relatively early stage of AD; therefore, the ques-
tion arose as to whether TENS would exert similar positive
effects in a more advanced stage of dementia. Consequently,
TENS was applied to AD patients (Global Deterioration Scale
stage 6, mean MMSE score 4.4 [range 3–7]),94 and the results
showed that only patients’ visual working memory signifi-
cantly improved; no effects were observed on other aspects of
memory processes or affective behavior. It is noteworthy,
though, that TENS appeared to have a beneficial effect on pa-
tients’ circadian rest-activity rhythm, similar to the observa-
tions in patients with an early stage of AD.95
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As previously emphasized, the “use it or lose it” concept
is not only applicable to AD but also to aging.60 The results of
a recent study show that TENS improved visual short-term and
verbal long-term (recognition) memory, and semantic verbal
fluency in nondemented elderly people.96 Moreover, stimu-
lated elderly subjects felt less depressed. Of note, the majority
of the observed effects could not be maintained during a treat-
ment-free period of 6 weeks, irrespective of dementia stage
and presence of a therapist.
A type of stimulation related to TENS is transcranial
electrostimulation (TCES, or TES). In one study, TCES in el-
derly patients with multi-infarct dementia was found to de-
crease wandering and nocturnal delirium and to enhance pa-
tients’ interaction with others.97 The authors suggest that this
effect might be partly mediated through the somatosensory
system. TCES recently has been applied to patients in an early
stage of AD. The results, however, showed no improvement in
cognition or affective behavior.98 Further studies are required
before firm conclusions on the effectiveness of TCES in AD
can be drawn.
In addition to nonpharmacological approaches targeting
cognitive function, other AD symptoms may respond well to
nonpharmacological intervention. An age-related decrease in
circadian modulation has been observed for several param-
eters, including hormone levels, temperature, electroencepha-
lographic activity, alertness, and sleep.99–101 Elderly people
start napping during the day and often complain of disturbed
sleep during the night (reviewed by Van Someren101), and in
AD, this fragmentation of the sleep/wake pattern is even more
pronounced. Such disturbances place strong demands on AD
caregivers and are among the most important reasons for insti-
tutionalization.100 The suprachiasmatic nucleus (SCN), which
is the biologic clock of the brain, is of critical importance in the
circadian modulation of behavior and physiology. Combined
anatomic, physiological, and behavioral findings suggest that a
dysfunctional clock may underlie the sleep/wake pattern frag-
mentation in the elderly and in AD patients.102–104 Therefore,
we tried a number of strategies designed to stimulate the cir-
cadian timing system to enhance the functionality of the clock.
Stimulation of the circadian timing system can be effected by
means of bright environmental light, peripheral nerve stimula-
tion, and increased levels of physical activity. Our studies in
aged rats have demonstrated improvement of both functional
and anatomic signs of the circadian timing system after envi-
ronmental stimulation. Moreover, Witting et al.105 demon-
strated that the decreased amplitude in the circadian distribu-
tion of sleep and wakefulness in old rats could be restored to
the level of young rats by increasing the intensity of daytime
environmental light. In humans, we have used the rest-activity
rhythm as a marker for the functionality of the circadian timing
system because this variable can be easily assessed using an
actigraph, which is a small wrist-worn solid-state recorder that
continuously assesses activity level, resulting in a time series
from which the strength of the circadian rhythm can be calcu-
lated. In a correlational study, we investigated which constitu-
tional and environmental factors were related to the severity of
rhythm disturbances in AD patients. Regression analyses
showed the most severe rest-activity rhythm disturbances in
patients with a sedentary lifestyle and in patients exposed to
low levels of environmental light.106 Subsequently, we inves-
tigated the effect of additional bright light on rest-activity
rhythm disturbances in demented patients. Additional bright
light improved the coupling of rest-activity rhythms to stable
environmental cues (so-called Zeitgebers) in patients with in-
tact vision (Fig. 2), but not in patients with severely compro-
mised sight (partial blindness, cataract).107 These results agree
with other studies showing improved circadian rhythms and
decreased behavioral disorders in AD patients treated with
bright light.108–111 The observation that light therapy also in-
creases MMSE scores in demented patients (pretreatment
mean MMSE score 15.2 ± 4.8; posttreatment mean MMSE
score 18.1 ± 4.5) makes light therapy of even greater interest
for AD research.112
Whereas the effect of light on the circadian timing sys-
tem is well documented, the possible effect of somatosensory
input to the SCN has only relatively recently been suggested by
our group.93 In rats and squirrel monkeys, it has been demon-
strated that the SCN is innervated by direct spinohypothalamic
projections conveying somatosensory information.113,114 We
therefore investigated whether additional somatosensory input
by means of TENS would provide an alternative means for the
activation of SCN neurons. Indeed, in early-stage demented
elderly people, repeated TENS was found to improve the cou-
pling of rest-activity rhythms to Zeitgebers, whereas placebo
treatment was ineffective.93 Similar effects also could be ob-
tained in later stages of AD.95 The anatomic and functional
findings from the reported studies in animals and humans in-
dicate that the SCN retains considerable plasticity during aging
and in demented elderly subjects.
POSTMORTEM PLASTICITY
Animal models for human neurologic and psychiatric
diseases only partially mimic the underlying pathogenic pro-
cesses. Therefore, we explored the potential use of postmortem
brain tissue cultures from adult neurologic patients and con-
trols.115–117 Organotypic human brain cultures obtained by au-
topsy within the framework of the Netherlands Brain Bank at 2
to 8 hours after death were maintained in vitro for extended
periods and manipulated experimentally. Slices in basal me-
dium supplemented with survival-promoting neurotrophic fac-
tors retain more viable cells than slices in basal medium alone.
Mitochondrial activity as measured by cytochrome oxidase ac-
tivity could be enhanced by the addition of pyruvate as an extra
energy source to the medium.
We have found that neurons in these cultures (motor cor-
tex, hippocampus, and cerebellum of adult postmortem brain)
Swaab et al. Alzheimer Dis Assoc Disord • Volume 17, Supplement 4, July–September 2003
S118 © 2003 Lippincott Williams & Wilkins
can be transduced with adeno-associated viral vectors express-
ing the reporter genes eGFP (enhanced green fluorescent pro-
tein) and lacZ for as long as 44 days.115–117 These slice cultures
offer new opportunities to study the cellular and molecular
mechanisms of aging and neurodegenerative diseases such as
AD, and to investigate potential treatments, including neuronal
reactivation.
CONCLUSION
An increasing body of evidence indicates that metabolic
impairment may contribute to neuronal dysfunction and atro-
phy in AD. The observations that glucose administration or
increasing glucose availability by experimentally inducing hy-
perinsulinemia enhances memory in patients with probable
AD118–120 support the view that AD is at least partially a hy-
pometabolic disease and also indicate that metabolic stimula-
tion of neurons appears to be a promising strategy.
Stimulation of neurons by other means, both pharmaco-
logical and nonpharmacological, also may at least partly re-
verse degenerative changes in aging and AD. The beneficial
effects of several types of neuronal stimulation may differ be-
tween age groups, stages of AD, APOE genotype, and status of
functional brain reserves, whether or not induced by early ex-
posure to a complex environment, profession, or education.
All these factors may impact the effectiveness of these strate-
gies. Furthermore, effectiveness may strongly depend on the
use of appropriate stimuli and the presence of receptors for
certain stimulating factors. Finally, human neurons in tissue
culture may serve as a model to test many stimulatory ap-
proaches, with the ultimate goal of increasing neuronal main-
tenance during aging and in AD.
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